Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
PLATINUM
PLATINUMG Stone (Columbia University Medical Center, NY)American College of Cardiology 2011 Scientific Sessions• Five-year...
PLATINUM: Results• The new platinum stent was noninferior to the control stent• Primary end point:   3.4% and 2.9% for the...
PLATINUM: Commentary*"The bar is set very high now."                                                                      ...
Become a member of http://www.theheart.org    Become a fan on Facebook: http://www.facebook.com/theheartorg          Follo...
Upcoming SlideShare
Loading in …5
×

PLATINUM trial - Summary & Results

576 views

Published on

http://www.theheart.org/web_slides/1232965.do

Five-year clinical trial on PLATINUM to assess the PROMUS Clement stent system for treatment of de novo coronary artery lesions

  • Be the first to comment

  • Be the first to like this

PLATINUM trial - Summary & Results

  1. 1. PLATINUM
  2. 2. PLATINUMG Stone (Columbia University Medical Center, NY)American College of Cardiology 2011 Scientific Sessions• Five-year clinical trial to assess the PROMUS Clement stent system for treatment of de novo coronary artery lesions: Promus Element contains the same drug (everolimus) and polymer as Xience V, with platinum scaffolding instead of cobalt to make the stent easier to use—more flexible, less chance of recoil, more radiopaque (easier to see)• Population and treatment: 1530 patients undergoing PCI in one or two coronary arteries Randomized to the new platinum stent or the cobalt stent• Primary outcome: 12-month rate of TLF: a composite of target-vessel-related cardiac death, target-vessel-related MI, or ischemia-driven TLR, in the per-protocol populationTLF: target lesion failureTLR: target lesion revascularization
  3. 3. PLATINUM: Results• The new platinum stent was noninferior to the control stent• Primary end point: 3.4% and 2.9% for the platinum and control stents, respectively (p for noninferiority=0.001; p for superiority=0.60)• No significant differences seen between the two in other safety/efficacy measures: Stent thrombosis: 0.4% in each group TLR: 1.9% in each group• Only 3.3% of the study population had adverse events
  4. 4. PLATINUM: Commentary*"The bar is set very high now." - Dr Charles J Davidson"When it comes to deciding which stent is better than another, it will come down tonuanced aspects, and these dont come to light until you are using these devices inlots and lots of people, not in these small trials designed for regulatory approval." - Dr Edward J McNulty"Its going to be difficult to distinguish these devices as being meaningfullydifferent." - Dr Martin Leon*All comments from Everolimus-eluting stent performs well in PLATINUM(http://www.theheart.org/article/1207155.do)
  5. 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×